Effects of canagliflozin on endothelial function and epicardial adipose tissue in patients with type 2 diabetes mellitus

Effects of canagliflozin on endothelial function and epicardial adipose tissue in patients with type 2 diabetes mellitus - Effects of canagliflozin on endothelial function and epicardial adipose tissue

Status

Recruiting

Phases

Unknown

Study type

Interventional

Source

JPRN

Registry ID

JPRN-UMIN000035355

Enrollment

Registered

2018-12-24

Start date

2018-12-25

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Type 2 diabetes mellitus

Interventions

Canagliflozin 100mg for 16 weeks

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: Patients with type 2 diabetes mellitus who have not never been prescribed SGLT2 inhibitors.

Exclusion criteria

Exclusion criteria: Patients with atrial fibrillation. Patient who is considered ineligible for enrolling this study by attending physician.

Design outcomes

Primary

Measure	Time frame
The changes of endothelial function using peripheral near infrared spectroscopy and epicardial adipose tissue using cardiac computed tomography	—

Secondary

Measure	Time frame
Body weight, abdominal circumference, lipid metabolism, renal function, comparison between patients with and without statin therapy.	—

Countries

Japan

Contacts

Public ContactKeiichiro Kuronuma

Kawaguchi Municipal Medical Center Department of Cardiology

keiichirokuronuma@gmail.com0482872525

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Jul 3, 2026